{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:04:18Z","timestamp":1769105058614,"version":"3.49.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy at the intersection of myelodysplastic (MDS) and myeloproliferative neoplasms, predominantly affecting older adults. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option, yet its application is limited by the advanced age and comorbidities of most patients. Recent classification updates and refined prognostic tools, particularly molecularly integrated models like CPSS-Mol have enhanced patient stratification and informed transplant timing. The aim of this review is to highlight the evolving landscape of CMML management, with a focus on the role of allo-HCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Novel studies patients demonstrated that individualized transplant timing significantly improved life expectancy. Optimizing transplant outcomes hinges on several factors:managing pretransplant splenomegaly, choosing appropriate debulking strategies, selecting optimal donors, and tailoring conditioning regimens. New data favor treosulfan-based and thiotepa-busulfan regimens for their favorable toxicity and relapse profiles. Post-transplant, strategies like post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis and emerging approaches to minimal residual disease (MRD) monitoring offer additional refinements in patient management. While no MRD studies are CMML-specific, extrapolation from MDS supports its role in relapse prediction. Innovative therapies, including hypomethylating agent combinations, venetoclax, targeted inhibitors, and immunotherapies are under active investigation, with potential to improve pre- and post-transplant outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Advancements in molecular classification, dynamic prognostic tools, and therapeutic strategies are reshaping the CMML treatment paradigm. Personalized approaches that integrate genetic risk, patient fitness, and disease characteristics are enabling more effective transplant strategies, with the ultimate goal of extending survival and improving quality of life in this complex and historically difficult-to-treat malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-025-00754-1","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T07:35:49Z","timestamp":1754897749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Transplant for CMML"],"prefix":"10.1007","volume":"20","author":[{"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihar","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","unstructured":"Patnaik MM. How I diagnose and treat chronic myelomonocytic leukemia. Haematologica 2022;107(7):1503\u201317. e-pub ahead of print 20220701;https:\/\/doi.org\/10.3324\/haematol.2021.279500","DOI":"10.3324\/haematol.2021.279500"},{"key":"754_CR2","doi-asserted-by":"publisher","unstructured":"Mangaonkar AA, Patnaik MM. Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis:novel mechanisms and insights into clonal propagation. Leuk Lymphoma 2022;63(8):1792\u20131800. e-pub ahead of print 20220404;https:\/\/doi.org\/10.1080\/10428194.2022.2056175","DOI":"10.1080\/10428194.2022.2056175"},{"key":"754_CR3","doi-asserted-by":"publisher","unstructured":"Marando L, Csizmar CM, Patnaik MM. Chronic myelomonocytic leukemia:molecular pathogenesis and therapeutic innovations. Haematologica 2025;110(1):22\u201336. e-pub ahead of print 20250101;https:\/\/doi.org\/10.3324\/haematol.2024.286061","DOI":"10.3324\/haematol.2024.286061"},{"key":"754_CR4","doi-asserted-by":"publisher","unstructured":"Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica 2019;104(10):1935\u20131949. e-pub ahead of print 20190502;https:\/\/doi.org\/10.3324\/haematol.2019.222059","DOI":"10.3324\/haematol.2019.222059"},{"key":"754_CR5","doi-asserted-by":"publisher","unstructured":"St Martin EC, Ferrer A, Wudhikarn K, Mangaonkar A, Hogan W, Tefferi A et al. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol 2021;96(9):E327-E330. e-pub ahead of print 20210604;https:\/\/doi.org\/10.1002\/ajh.26250","DOI":"10.1002\/ajh.26250"},{"issue":"3","key":"754_CR6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3324\/haematol.2019.240853","volume":"105","author":"GF Sanz","year":"2020","unstructured":"Sanz GF, Ibanez M, Mora E. Are next-generation sequencing results knocking on heaven\u2019s door for transplantation planning in chronic myelomonocytic leukemia? Haematologica. 2020;105(3):530\u20133. https:\/\/doi.org\/10.3324\/haematol.2019.240853.","journal-title":"Haematologica"},{"key":"754_CR7","doi-asserted-by":"publisher","unstructured":"Coltro G, Patnaik MM. Chronic Myelomonocytic Leukemia:Insights into Biology, Prognostic Factors, and Treatment. Curr Oncol Rep 2019;21(11):101. e-pub ahead of print 20191114;https:\/\/doi.org\/10.1007\/s11912-019-0855-6","DOI":"10.1007\/s11912-019-0855-6"},{"key":"754_CR8","doi-asserted-by":"publisher","unstructured":"Patnaik MM, Tefferi A, Garcia-Manero G. Blast-phase chronic myelomonocytic leukemia:more than just semantics. Leukemia 2018;32(9):2093\u20132094. e-pub ahead of print 20180807;https:\/\/doi.org\/10.1038\/s41375-018-0228-4","DOI":"10.1038\/s41375-018-0228-4"},{"issue":"1","key":"754_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","volume":"95","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia:2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97\u2013115. https:\/\/doi.org\/10.1002\/ajh.25684.","journal-title":"Am J Hematol"},{"key":"754_CR10","doi-asserted-by":"publisher","unstructured":"Gibson CJ, Kim HT, Zhao L, Murdock HM, Hambley B, Ogata A et al. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol 2022;40(2):189\u2013201. e-pub ahead of print 20211118;https:\/\/doi.org\/10.1200\/JCO.21.02286","DOI":"10.1200\/JCO.21.02286"},{"issue":"1","key":"754_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","volume":"118","author":"N Kroger","year":"2002","unstructured":"Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol. 2002;118(1):67\u201373. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03552.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"754_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.13576","volume":"171","author":"A Symeonidis","year":"2015","unstructured":"Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic Haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the chronic malignancies working party of the European group for blood and marrow transplantation. Br J Haematol. 2015;171(2):239\u201346. https:\/\/doi.org\/10.1111\/bjh.13576. e-pub ahead of print 20150726.","journal-title":"Br J Haematol"},{"issue":"9","key":"754_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2013.084020","volume":"98","author":"F Onida","year":"2013","unstructured":"Onida F, Barosi G, Leone G, Malcovati L, Morra E, Santini V, et al. Management recommendations for chronic myelomonocytic leukemia:consensus statements from the SIE, SIES, GITMO groups. Haematologica. 2013;98(9):1344\u201352. https:\/\/doi.org\/10.3324\/haematol.2013.084020.","journal-title":"Haematologica"},{"key":"754_CR14","doi-asserted-by":"publisher","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 2022;36(7):1703\u20131719. e-pub ahead of print 20220622;https:\/\/doi.org\/10.1038\/s41375-022-01613-1","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"11","key":"754_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias:integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"12","key":"754_CR16","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood.2023021199","volume":"143","author":"F Baumgartner","year":"2024","unstructured":"Baumgartner F, Baer C, Bamopoulos S, Ayoub E, Truger M, Meggendorfer M, et al. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022. Blood. 2024;143(12):1139\u201356. https:\/\/doi.org\/10.1182\/blood.2023021199.","journal-title":"Blood"},{"issue":"6","key":"754_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11899-017-0416-8","volume":"12","author":"F Onida","year":"2017","unstructured":"Onida F. Models of prognostication in chronic myelomonocytic leukemia. Curr Hematol Malig Rep. 2017;12(6):513\u201321. https:\/\/doi.org\/10.1007\/s11899-017-0416-8.","journal-title":"Curr Hematol Malig Rep"},{"key":"754_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027170","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, et al. BLAST:A globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024027170. e-pub ahead of print 20250507.","journal-title":"Blood"},{"issue":"12","key":"754_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood.2021015173","volume":"140","author":"M Robin","year":"2022","unstructured":"Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, et al. Role of allogeneic transplantation in chronic myelomonocytic leukemia:an international collaborative analysis. Blood. 2022;140(12):1408\u201318. https:\/\/doi.org\/10.1182\/blood.2021015173.","journal-title":"Blood"},{"key":"754_CR20","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Bogdanov R, Stolzel F, Rautenberg C, Panagiota V, Becker H et al. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Transplant Cell Ther 2021;27(1):95 e91-95 e94. e-pub ahead of print 20201009;https:\/\/doi.org\/10.1016\/j.bbmt.2020.10.007","DOI":"10.1016\/j.bbmt.2020.10.007"},{"issue":"22","key":"754_CR21","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood.2023023476","volume":"143","author":"F Onida","year":"2024","unstructured":"Onida F, Gagelmann N, Chalandon Y, Kobbe G, Robin M, Symeonidis A, et al. Management of adult patients with CMML undergoing allo-HCT:recommendations from the EBMT PH&G committee. Blood. 2024;143(22):2227\u201344. https:\/\/doi.org\/10.1182\/blood.2023023476.","journal-title":"Blood"},{"issue":"1","key":"754_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/MOH.0000000000000553","volume":"27","author":"RM Carr","year":"2020","unstructured":"Carr RM, Patnaik MM. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. Curr Opin Hematol. 2020;27(1):2\u201310. https:\/\/doi.org\/10.1097\/MOH.0000000000000553.","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"754_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41375-023-01820-4","volume":"37","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023;37(3):717\u20139. https:\/\/doi.org\/10.1038\/s41375-023-01820-4. e-pub ahead of print 20230128.","journal-title":"Leukemia"},{"key":"754_CR24","doi-asserted-by":"publisher","unstructured":"Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S et al. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. J Clin Oncol 2024;42(24):2873\u20132886. e-pub ahead of print 20240509;https:\/\/doi.org\/10.1200\/JCO.23.02175","DOI":"10.1200\/JCO.23.02175"},{"issue":"6","key":"754_CR25","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/bloodadvances.2020003600","volume":"5","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Badbaran A, Beelen DW, Salit RB, Stolzel F, Rautenberg C, et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021;5(6):1760\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2020003600.","journal-title":"Blood Adv"},{"key":"754_CR26","doi-asserted-by":"publisher","unstructured":"Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N et al. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia 2023;37(8):1753\u20131756. e-pub ahead of print 20230708;https:\/\/doi.org\/10.1038\/s41375-023-01964-3","DOI":"10.1038\/s41375-023-01964-3"},{"key":"754_CR27","unstructured":"Della Porta MG, Lannino L, Flamigni A, Hunter AM, Gagelmann N, Robin M et al. A DECISION SUPPORT SYSTEM FOR PERSONALIZED OPTIMIZATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION TIMING IN CHRONIC MYELOMONOCYTIC LEUKEMIA. EHA 2025:S176."},{"key":"754_CR28","doi-asserted-by":"publisher","unstructured":"Zhou C, Xu L, Zhang X, Chang Y, Mo X, Sun Y et al. Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes. Bone Marrow Transplant 2025;60(4):467\u2013473. e-pub ahead of print 20250122;https:\/\/doi.org\/10.1038\/s41409-025-02511-7","DOI":"10.1038\/s41409-025-02511-7"},{"issue":"4","key":"754_CR29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ajh.27632","volume":"100","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Kroger N. It\u2019s more than complex:further insights into TP53 in MPN. Am J Hematol. 2025;100(4):546\u20137. https:\/\/doi.org\/10.1002\/ajh.27632. e-pub ahead of print 20250208.","journal-title":"Am J Hematol"},{"issue":"28","key":"754_CR30","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across High-Risk genetic subgroups:genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41(28):4497\u2013510. https:\/\/doi.org\/10.1200\/JCO.23.00866. e-pub ahead of print 20230822.","journal-title":"J Clin Oncol"},{"issue":"1","key":"754_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3324\/haematol.2021.280203","volume":"108","author":"M Mei","year":"2023","unstructured":"Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, et al. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes:a center for blood and marrow transplantation research (CIBMTR) analysis. Haematologica. 2023;108(1):150\u201360. https:\/\/doi.org\/10.3324\/haematol.2021.280203. e-pub ahead of print 20230101.","journal-title":"Haematologica"},{"issue":"3","key":"754_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41409-024-02480-3","volume":"60","author":"JY Zhou","year":"2025","unstructured":"Zhou JY, Chen YX, Yuan HL, Xu YJ, Huang XB, Gao SJ, et al. A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT:a nationwide representative multicenter study. Bone Marrow Transpl. 2025;60(3):310\u20138. https:\/\/doi.org\/10.1038\/s41409-024-02480-3. e-pub ahead of print 20241125.","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"754_CR33","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/ajh.26999","volume":"98","author":"JY Zhou","year":"2023","unstructured":"Zhou JY, Wang S, Yuan HL, Xu YJ, Huang XB, Gao SJ, et al. Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML. Am J Hematol. 2023;98(9):1394\u2013406. https:\/\/doi.org\/10.1002\/ajh.26999. e-pub ahead of print 20230627.","journal-title":"Am J Hematol"},{"issue":"11","key":"754_CR34","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/ajh.25246","volume":"93","author":"P Pophali","year":"2018","unstructured":"Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, et al. Splenectomy in patients with chronic myelomonocytic leukemia:indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. Am J Hematol. 2018;93(11):1347\u201357. https:\/\/doi.org\/10.1002\/ajh.25246. e-pub ahead of print 20181005.","journal-title":"Am J Hematol"},{"issue":"5","key":"754_CR35","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ajh.27252","volume":"99","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation:A global collaborative analysis. Am J Hematol. 2024;99(5):844\u201353. https:\/\/doi.org\/10.1002\/ajh.27252. e-pub ahead of print 20240215.","journal-title":"Am J Hematol"},{"key":"754_CR36","doi-asserted-by":"publisher","unstructured":"Hunter AM, Newman H, Dezern AE, Steensma DP, Niyongere S, Roboz GJ et al. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res 2021;27(22):6095\u20136105. e-pub ahead of print 20210712;https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0935","DOI":"10.1158\/1078-0432.CCR-21-0935"},{"key":"754_CR37","doi-asserted-by":"publisher","unstructured":"Sanz GF. A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 2017;23(5):713\u2013714. e-pub ahead of print 20170309;https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.011","DOI":"10.1016\/j.bbmt.2017.03.011"},{"key":"754_CR38","doi-asserted-by":"publisher","unstructured":"Robin M, Fenaux P. Hypomethylating Agents as Bridging Therapy before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myelomonocytic Leukemia? Biol Blood Marrow Transplant 2016;22(1):1\u20132. e-pub ahead of print 20151111;https:\/\/doi.org\/10.1016\/j.bbmt.2015.11.004","DOI":"10.1016\/j.bbmt.2015.11.004"},{"issue":"13","key":"754_CR39","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML:recommendations from an international expert panel. Blood. 2017;129(13):1753\u201362. https:\/\/doi.org\/10.1182\/blood-2016-06-724500. e-pub ahead of print 20170117.","journal-title":"Blood"},{"key":"754_CR40","doi-asserted-by":"publisher","unstructured":"Wedge E, Hansen JW, Dybedal I, Creignou M, Ejerblad E, Lorenz F et al. Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia:Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. Transplant Cell Ther 2021;27(12):991 e991-991 e999. e-pub ahead of print 20210906;https:\/\/doi.org\/10.1016\/j.jtct.2021.08.028","DOI":"10.1016\/j.jtct.2021.08.028"},{"key":"754_CR41","doi-asserted-by":"publisher","unstructured":"Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D et al. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol 2021;39(30):3318\u20133327. e-pub ahead of print 20210720;https:\/\/doi.org\/10.1200\/JCO.20.02724","DOI":"10.1200\/JCO.20.02724"},{"key":"754_CR42","doi-asserted-by":"publisher","unstructured":"Neuendorff NR, Gagelmann N, Singhal S, Meckstroth S, Thibaud V, Zhao Y et al. Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. J Geriatr Oncol 2023;14(3):101406. e-pub ahead of print 20221123;https:\/\/doi.org\/10.1016\/j.jgo.2022.11.005","DOI":"10.1016\/j.jgo.2022.11.005"},{"key":"754_CR43","doi-asserted-by":"publisher","unstructured":"Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia:Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol 2023;41(10):1888\u20131897. e-pub ahead of print 20221201;https:\/\/doi.org\/10.1200\/JCO.22.00437","DOI":"10.1200\/JCO.22.00437"},{"key":"754_CR44","doi-asserted-by":"publisher","unstructured":"Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D et al. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia:a propensity score matched multicenter cohort study. Leukemia 2025;39(1):257\u2013260. e-pub ahead of print 20241112;https:\/\/doi.org\/10.1038\/s41375-024-02466-6","DOI":"10.1038\/s41375-024-02466-6"},{"key":"754_CR45","doi-asserted-by":"publisher","unstructured":"Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia:a propensity score-matched study. Blood Cancer J 2025;15(1):50. e-pub ahead of print 20250331;https:\/\/doi.org\/10.1038\/s41408-025-01245-5","DOI":"10.1038\/s41408-025-01245-5"},{"issue":"1","key":"754_CR46","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN):a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11(1):e15\u201326. https:\/\/doi.org\/10.1016\/S2352-3026(23)00338-1.","journal-title":"Lancet Haematol"},{"key":"754_CR47","doi-asserted-by":"publisher","unstructured":"Briski R, Garcia-Manero G, Kantarjian H, Ravandi F. The history of oral decitabine\/cedazuridine and its potential role in acute myeloid leukemia. Ther Adv Hematol 2023;14:20406207231205429. e-pub ahead of print 20231017;https:\/\/doi.org\/10.1177\/20406207231205429","DOI":"10.1177\/20406207231205429"},{"issue":"6","key":"754_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, et al. Oral cedazuridine\/decitabine for MDS and CMML:a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020;136(6):674\u201383. https:\/\/doi.org\/10.1182\/blood.2019004143.","journal-title":"Blood"},{"issue":"4","key":"754_CR49","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","volume":"6","author":"MR Savona","year":"2019","unstructured":"Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, et al. An oral fixed-dose combination of decitabine and Cedazuridine in myelodysplastic syndromes:a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6(4):e194\u2013203. https:\/\/doi.org\/10.1016\/S2352-3026(19)30030-4.","journal-title":"Lancet Haematol"},{"key":"754_CR50","doi-asserted-by":"publisher","unstructured":"Kurosawa S, Shimomura Y, Ishiyama K, Fuse K, Shimazu Y, Doki N et al. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia:a nationwide study. Bone Marrow Transplant 2024;59(6):742\u2013750. e-pub ahead of print 20240208;https:\/\/doi.org\/10.1038\/s41409-024-02223-4","DOI":"10.1038\/s41409-024-02223-4"},{"key":"754_CR51","doi-asserted-by":"publisher","unstructured":"Bergland BS, Remberger M, Tjonnfjord GE, Vo CD, Myhre AE, Abrahamsen IW et al. Should a young matched unrelated donor be preferred over an older matched related donor in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome? Bone marrow transplant 2025. e-pub ahead of print 20250418;https:\/\/doi.org\/10.1038\/s41409-025-02579-1","DOI":"10.1038\/s41409-025-02579-1"},{"key":"754_CR52","doi-asserted-by":"publisher","unstructured":"Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM et al. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome:A Large Single-Center Analysis. Transplant Cell Ther 2024;30(7):687 e681-687 e613. e-pub ahead of print 20240503;https:\/\/doi.org\/10.1016\/j.jtct.2024.05.001","DOI":"10.1016\/j.jtct.2024.05.001"},{"key":"754_CR53","doi-asserted-by":"publisher","unstructured":"Pereira MP, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R et al. Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation:Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Transplant Cell Ther 2023;29(11):697 e691-697 e610. e-pub ahead of print 20230812;https:\/\/doi.org\/10.1016\/j.jtct.2023.08.009","DOI":"10.1016\/j.jtct.2023.08.009"},{"key":"754_CR54","doi-asserted-by":"publisher","unstructured":"Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA et al. Haploidentical donor hematopoietic cell transplantation for myelodysplastic\/myeloproliferative overlap neoplasms:results from a North American collaboration. Haematologica 2023;108(12):3321\u20133332. e-pub ahead of print 20231201;https:\/\/doi.org\/10.3324\/haematol.2023.283426","DOI":"10.3324\/haematol.2023.283426"},{"issue":"12","key":"754_CR55","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","volume":"5","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers:A systematic review and Meta-analysis. JAMA Oncol. 2019;5(12):1739\u201348. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3541.","journal-title":"JAMA Oncol"},{"key":"754_CR56","doi-asserted-by":"publisher","unstructured":"Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N et al. Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia:A Nationwide Retrospective Analysis in Japan. Biol Blood Marrow Transplant 2018;24(4):840\u2013848. e-pub ahead of print 20171128;https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.016","DOI":"10.1016\/j.bbmt.2017.11.016"},{"issue":"18","key":"754_CR57","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2024024345","volume":"143","author":"K Fleischhauer","year":"2024","unstructured":"Fleischhauer K. Hidden treasures of histocompatibility. Blood. 2024;143(18):1792\u20134. https:\/\/doi.org\/10.1182\/blood.2024024345.","journal-title":"Blood"},{"issue":"16","key":"754_CR58","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood.2024024351","volume":"144","author":"E Arrieta-Bolanos","year":"2024","unstructured":"Arrieta-Bolanos E, van der Burg LLJ, Gedde-Dahl T, Robin M, Salmenniemi U, Kroger N, et al. Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS. Blood. 2024;144(16):1747\u201351. https:\/\/doi.org\/10.1182\/blood.2024024351.","journal-title":"Blood"},{"key":"754_CR59","doi-asserted-by":"publisher","unstructured":"Arrieta-Bolanos E, Bonneville EF, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U et al. Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol 2024;42(28):3287\u20133299. e-pub ahead of print 20240821;https:\/\/doi.org\/10.1200\/JCO.24.00582","DOI":"10.1200\/JCO.24.00582"},{"issue":"3","key":"754_CR60","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","volume":"8","author":"GS Guru Murthy","year":"2022","unstructured":"Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, et al. Relapse and Disease-Free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 2022;8(3):404\u201311. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6846.","journal-title":"JAMA Oncol"},{"key":"754_CR61","doi-asserted-by":"publisher","unstructured":"Sun YQ, Wu LX, Zhang YC, Xu YJ, Huang XB, Ye BD et al. Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia:A multicenter real-world study. Int J Cancer 2025 e-pub ahead Print 20250526;https:\/\/doi.org\/10.1002\/ijc.35485","DOI":"10.1002\/ijc.35485"},{"key":"754_CR62","doi-asserted-by":"publisher","unstructured":"Konishi T, Matsuda K, Itonaga H, Doki N, Nishida T, Matsuoka KI et al. Impact of Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients With Myelodysplastic Syndrome:A Nationwide Retrospective Study From Adult Myelodysplastic Syndrome Working Group of the JSTCT. Transplant Cell Ther 2024;30(7):685 e681-685 e612. e-pub ahead of print 20240430;https:\/\/doi.org\/10.1016\/j.jtct.2024.04.019","DOI":"10.1016\/j.jtct.2024.04.019"},{"key":"754_CR63","doi-asserted-by":"publisher","unstructured":"Duke ER, Williamson BD, Borate B, Golob JL, Wychera C, Stevens-Ayers T, et al. CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. J Clin Invest. 2021;131(1). https:\/\/doi.org\/10.1172\/JCI133960.","DOI":"10.1172\/JCI133960"},{"issue":"8","key":"754_CR64","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/cid\/ciz490","volume":"70","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70(8):1525\u201333. https:\/\/doi.org\/10.1093\/cid\/ciz490.","journal-title":"Clin Infect Dis"},{"key":"754_CR65","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Ljungman P, Styczynski J, Kroger N. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation:A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24(10):2101\u20132109. e-pub ahead of print 20180516;https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.017","DOI":"10.1016\/j.bbmt.2018.05.017"},{"issue":"25","key":"754_CR66","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in Hematopoietic-Cell transplantation. N Engl J Med. 2017;377(25):2433\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1706640. e-pub ahead of print 20171206.","journal-title":"N Engl J Med"},{"issue":"8","key":"754_CR67","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27363","volume":"99","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Schuh C, Flossdorf S, Kunadt D, Stelljes M, Blau IW, et al. Impact of Busulfan versus Treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation. Am J Hematol. 2024;99(8):1540\u20139. https:\/\/doi.org\/10.1002\/ajh.27363. e-pub ahead of print 20240514.","journal-title":"Am J Hematol"},{"key":"754_CR68","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Kroger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation:can we recommend when and for whom in 2021? Haematologica 2021;106(7):1794\u20131804. e-pub ahead of print 20210701;https:\/\/doi.org\/10.3324\/haematol.2020.268839","DOI":"10.3324\/haematol.2020.268839"},{"key":"754_CR69","doi-asserted-by":"publisher","unstructured":"Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A et al. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation:a retrospective study by the chronic malignancies working party of the EBMT. Bone Marrow Transplant 2024;59(2):224\u2013231. e-pub ahead of print 20231122;https:\/\/doi.org\/10.1038\/s41409-023-02111-3","DOI":"10.1038\/s41409-023-02111-3"},{"key":"754_CR70","doi-asserted-by":"publisher","unstructured":"Niederwieser C, Iacobelli S, Franke GN, Koster L, van Os M, Platzbecker U et al. Reduced intensity versus myeloablative conditioning for MDS:long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant 2024;59(8):1084\u20131091. e-pub ahead of print 20240425;https:\/\/doi.org\/10.1038\/s41409-024-02282-7","DOI":"10.1038\/s41409-024-02282-7"},{"key":"754_CR71","doi-asserted-by":"publisher","unstructured":"Kroger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hubel K et al. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome:A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol 2017;35(19):2157\u20132164. e-pub ahead of print 20170502;https:\/\/doi.org\/10.1200\/JCO.2016.70.7349","DOI":"10.1200\/JCO.2016.70.7349"},{"key":"754_CR72","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica 2019;104(5):929\u2013936. e-pub ahead of print 20190117;https:\/\/doi.org\/10.3324\/haematol.2018.200808","DOI":"10.3324\/haematol.2018.200808"},{"key":"754_CR73","doi-asserted-by":"publisher","unstructured":"Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C et al. Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients. Transplant Cell Ther 2025;31(1):20 e21-20 e14. e-pub ahead of print 20241016;https:\/\/doi.org\/10.1016\/j.jtct.2024.10.003","DOI":"10.1016\/j.jtct.2024.10.003"},{"issue":"Suppl 4","key":"754_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ajh.27660","volume":"100","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Kroger N. Allogeneic stem cell transplant for myelofibrosis and myelodysplastic syndromes:A contemporary review. Am J Hematol. 2025;100(Suppl 4):16\u201329. https:\/\/doi.org\/10.1002\/ajh.27660. e-pub ahead of print 20250313.","journal-title":"Am J Hematol"},{"key":"754_CR75","doi-asserted-by":"publisher","unstructured":"Cassanello G, Serpenti F, Bagnoli F, Saporiti G, Goldaniga M, Cavallaro F et al. Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes:a single center experience. Bone Marrow Transplant 2023;58(9):1059\u20131061. e-pub ahead of print 20230624;https:\/\/doi.org\/10.1038\/s41409-023-02023-2","DOI":"10.1038\/s41409-023-02023-2"},{"key":"754_CR76","doi-asserted-by":"publisher","unstructured":"Pasic I, Moya TA, Remberger M, Chen C, Gerbitz A, Kim DDH et al. Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome:A Single-center Retrospective Propensity Score-matched Cohort Study. Transplant Cell Ther 2024;30(7):681 e681-681 e611. e-pub ahead of print 20240420;https:\/\/doi.org\/10.1016\/j.jtct.2024.04.014","DOI":"10.1016\/j.jtct.2024.04.014"},{"key":"754_CR77","doi-asserted-by":"publisher","unstructured":"Cao YG, He Y, Zhang SD, Liu ZX, Zhai WH, Ma QL et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms. Biol Blood Marrow Transplant 2020;26(2):285\u2013291. e-pub ahead of print 20190905;https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.001","DOI":"10.1016\/j.bbmt.2019.09.001"},{"key":"754_CR78","doi-asserted-by":"publisher","unstructured":"Desai N, Rodriguez-Rodriguez S, Chen C, Moya TA, Al-Shaibani E, Novitzky-Basso I et al. Outcomes of allogeneic hematopoietic stem cell transplantation for myelodysplastic\/myeloproliferative overlap neoplasms. Eur J Haematol 2025 e-pub ahead Print 20250507;https:\/\/doi.org\/10.1111\/ejh.14430","DOI":"10.1111\/ejh.14430"},{"issue":"4","key":"754_CR79","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2020.271445","volume":"107","author":"R Massoud","year":"2022","unstructured":"Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, et al. Comparison of immune reconstitution between anti-T-lymphocyte Globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica. 2022;107(4):857\u201367. https:\/\/doi.org\/10.3324\/haematol.2020.271445. e-pub ahead of print 20220401.","journal-title":"Haematologica"},{"issue":"11","key":"754_CR80","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","volume":"379","author":"EJ Duncavage","year":"2018","unstructured":"Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, et al. Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018;379(11):1028\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1804714.","journal-title":"N Engl J Med"},{"key":"754_CR81","doi-asserted-by":"publisher","unstructured":"Hou C, Zhou L, Yang M, Jiang S, Shen H, Zhu M et al. The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation. Front Oncol 2021;11:700234. e-pub ahead of print 20210805;https:\/\/doi.org\/10.3389\/fonc.2021.700234","DOI":"10.3389\/fonc.2021.700234"},{"issue":"2","key":"754_CR82","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa2408941","volume":"392","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Luck C, et al. Clearance of driver mutations after transplantation for myelofibrosis. N Engl J Med. 2025;392(2):150\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2408941.","journal-title":"N Engl J Med"},{"key":"754_CR83","doi-asserted-by":"publisher","unstructured":"Tobiasson M, Pandzic T, Illman J, Nilsson L, Westrom S, Ejerblad E et al. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation. J Clin Oncol 2024;42(12):1378\u20131390. e-pub ahead of print 20240117;https:\/\/doi.org\/10.1200\/JCO.23.01159","DOI":"10.1200\/JCO.23.01159"},{"issue":"11","key":"754_CR84","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1182\/blood.2023022851","volume":"143","author":"M Dimitriou","year":"2024","unstructured":"Dimitriou M, Mortera-Blanco T, Tobiasson M, Mazzi S, Lehander M, Hogstrand K, et al. Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation. Blood. 2024;143(11):953\u201366. https:\/\/doi.org\/10.1182\/blood.2023022851.","journal-title":"Blood"},{"issue":"3","key":"754_CR85","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ijlh.13788","volume":"44","author":"X Pan","year":"2022","unstructured":"Pan X, Gao M, Sun Y, Zhou Y, Wang K, Wang Y, et al. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol. 2022;44(3):510\u20137. https:\/\/doi.org\/10.1111\/ijlh.13788. e-pub ahead of print 20220121.","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"754_CR86","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","volume":"37","author":"MA Elliott","year":"2006","unstructured":"Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transpl. 2006;37(11):1003\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1705369.","journal-title":"Bone Marrow Transpl"},{"key":"754_CR87","doi-asserted-by":"publisher","unstructured":"Miller KC, Abdel Rahman ZH, Robetorye RS, Foran JM. Donor cell-derived chronic myelomonocytic leukemia presenting after allogeneic hematopoietic cell transplantation for T-cell acute lymphoblastic leukemia. Clin Case Rep 2020;8(12):3225\u20133228. e-pub ahead of print 20201007;https:\/\/doi.org\/10.1002\/ccr3.3383","DOI":"10.1002\/ccr3.3383"},{"issue":"3","key":"754_CR88","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000534315","volume":"147","author":"L Minculescu","year":"2024","unstructured":"Minculescu L, Reekie J, Petersen SL, Kornblit BT, Schjoedt I, Andersen NS, et al. Donor lymphocyte infusion is a feasible way to improve survival in patients with acute myeloid leukemia and myelodysplastic syndromes who relapse after allogeneic stem cell transplantation. Acta Haematol. 2024;147(3):325\u201332. https:\/\/doi.org\/10.1159\/000534315. e-pub ahead of print 20231012.","journal-title":"Acta Haematol"},{"key":"754_CR89","doi-asserted-by":"publisher","unstructured":"Marumo A, Nagata Y, Fujioka M, Kurosawa S, Najima Y, Sakaida E et al. Outcome of donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in relapsed myelodysplastic syndrome. Cytotherapy 2025;27(2):222\u2013228. e-pub ahead of print 20241017;https:\/\/doi.org\/10.1016\/j.jcyt.2024.09.006","DOI":"10.1016\/j.jcyt.2024.09.006"},{"key":"754_CR90","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kroger N. TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia:A Systematic Review and Meta-Analysis. Front Immunol 2021;12:630429. e-pub ahead of print 20210312;https:\/\/doi.org\/10.3389\/fimmu.2021.630429","DOI":"10.3389\/fimmu.2021.630429"},{"key":"754_CR91","doi-asserted-by":"publisher","unstructured":"Indran T, Das T, Muirhead J, O\u2019Brien M, Swain MI, Cirone B et al. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34(+) and CD3(+) donor chimerism (DC) monitoring. Leuk Res 2024;142:107504. e-pub ahead of print 20240424;https:\/\/doi.org\/10.1016\/j.leukres.2024.107504","DOI":"10.1016\/j.leukres.2024.107504"},{"issue":"1","key":"754_CR92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41409-021-01464-x","volume":"57","author":"X Poire","year":"2022","unstructured":"Poire X, Graux C, Ory A, Herman J, Baron F, Schoemans H, et al. Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT):a prospective study from the Belgian hematology society (BHS). Bone Marrow Transpl. 2022;57(1):116\u20138. https:\/\/doi.org\/10.1038\/s41409-021-01464-x. e-pub ahead of print 20211005.","journal-title":"Bone Marrow Transpl"},{"key":"754_CR93","doi-asserted-by":"publisher","unstructured":"Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D. Donor lymphocyte infusions in AML and MDS:Enhancing the graft-versus-leukemia effect. Exp Hematol 2017;48:1\u201311. e-pub ahead of print 20161224;https:\/\/doi.org\/10.1016\/j.exphem.2016.12.004","DOI":"10.1016\/j.exphem.2016.12.004"},{"key":"754_CR94","doi-asserted-by":"publisher","unstructured":"Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013;27(6):1229\u20131235. e-pub ahead of print 20130114;https:\/\/doi.org\/10.1038\/leu.2013.7","DOI":"10.1038\/leu.2013.7"},{"key":"754_CR95","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E et al. Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation. Hemasphere 2023;7(7):e921. e-pub ahead of print 20230630;https:\/\/doi.org\/10.1097\/HS9.0000000000000921","DOI":"10.1097\/HS9.0000000000000921"},{"key":"754_CR96","doi-asserted-by":"publisher","unstructured":"Lasho T, Patnaik MM. Novel therapeutic targets for chronic myelomonocytic leukemia. Best Pract Res Clin Haematol 2021;34(1):101244. e-pub ahead of print 20210116;https:\/\/doi.org\/10.1016\/j.beha.2021.101244","DOI":"10.1016\/j.beha.2021.101244"},{"key":"754_CR97","doi-asserted-by":"publisher","unstructured":"Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2022;63(13):3154\u20133164. e-pub ahead of print 20220905;https:\/\/doi.org\/10.1080\/10428194.2022.2116932","DOI":"10.1080\/10428194.2022.2116932"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00754-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:19:44Z","timestamp":1769044784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00754-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00754-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"5 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10"}}